Seaport Therapeutics Secures $225M in Oversubscribed Series B Financing to Propel Neuropsychiatric Drug Development

Boston, MA, October 21, 2024 (Business Wire) -- Seaport Therapeutics has raised $225 million in a Series B financing round led by General Atlantic to advance its neuropsychiatric drug pipeline. The funding will support the development of its Glyph technology platform, which enhances oral bioavailability and reduces side effects. Overall, Seaport has now secured $325 million since its launch in April 2024.

Read full article here.